Neuren (NEU) – ASX Announcement **17 November 2026**

Acadia enters exclusive distribution agreement for DAYBUE® STIX in Japan

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU)'s exclusive global partner for trofinetide, Acadia Pharmaceuticals (Nasdaq: ACAD), has announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX in Japan. Acadia's full announcement is available in the Investors section of the Acadia website www.acadia.com.

Acadia recently completed the Phase 3 study of trofinetide in Rett syndrome in Japan, with results consistent with the LAVENDER™ Phase 3 study and supportive of a planned regulatory filing.

Neuren CEO Jon Pilcher commented: "We are pleased to see our partner Acadia making progress in preparation for the anticipated regulatory filing in Japan in 2027, with a potential launch in 2028 subject to regulatory approval."

Under Neuren's licence agreement with Acadia, for Japan, Neuren is entitled to receive US$15 million following first commercial sale, potential sales milestone payments of up to US$110 million on achievement of escalating annual net sales thresholds, and tiered royalties ranging from mid-teens to low-twenties percentage of net sales.

Click **here** to view this announcement on our Investor Hub.

About Neuren

Neuren Pharmaceuticals is developing new drug therapies to treat multiple serious neurological disorders caused by genetic abnormalities or brain injury, that have no or limited approved treatment options. Neuren's therapies target the critical role of Insulin-like growth factor 1 (IGF-1) in the brain, using orally administered analogs of naturally occurring peptides.

DAYBUE® (trofinetide) oral solution and DAYBUE STIX (trofinetide) powder are approved for the treatment of Rett syndrome by the US Food and Drug Administration (FDA). The oral solution is also approved by the European Medicines Agency, Health Canada and the Ministry of Health in Israel. Neuren has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren's investigative drug candidate, NNZ-2591 (ercanetide), is in clinical development as an oral solution treatment for multiple neurodevelopmental disorders, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Each of these programs has been granted "orphan drug" designation in the United States and the European Union as well as Fast Track and Rare Pediatric Disease designations from the FDA. NNZ-2591 has also been granted orphan drug designation for the treatment of hypoxic ischemic encephalopathy (HIE), a serious condition caused by brain injury before or shortly after birth.

Currently, Neuren is conducting a Phase 3, randomized, double-blind, placebo-controlled clinical trial ("Koala") evaluating the safety and efficacy of NNZ-2591 in children aged 3 to 12 years with Phelan-McDermid syndrome and a 52-week open-label extension study.

Investor contact:
Jon Pilcher, CEO & Managing Director
+61 438 422 271
investorrelations@neurenpharma.com

Media Contact:
Monsoon Communications
Rudi Michelson
rudim@monsoon.com.au

Investor Hub

ASX Listing Rules information

This announcement was authorized to be given to the ASX by the Board of Neuren Pharmaceuticals Limited, Suite 1.01, 117 Camberwell Road, Hawthorn East, VIC 3123

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.